Глобальный рынок тяжелого комбинированного иммунодефицита – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка тяжелого комбинированного иммунодефицита

Тяжелый комбинированный иммунодефицит — редкие формы генетических нарушений, которые могут быть фатальными для младенца, если их не лечить своевременно. Прогнозируется, что рост осведомленности о скрининге и диагностике этих нарушений увеличит мировой рынок лечения тяжелого комбинированного иммунодефицита. Доступность лекарств и иммунологически связанных методов лечения, вероятно, увеличит рост рынка тяжелого комбинированного иммунодефицита в прогнозируемом временном интервале с 2023 по 2030 год. Ожидается, что технологические достижения в области методов скрининга будут способствовать росту мирового рынка лечения тяжелого комбинированного иммунодефицита. Внедрение терапии стволовыми клетками, генной терапии и других методов лечения также, вероятно, будет способствовать развитию мирового рынка. Более того, для лечения детей с тяжелым комбинированным иммунодефицитом обычно рекомендуются инфузия антител и трансплантация костного мозга.

Data Bridge Market Research анализирует, что рынок тяжелого комбинированного иммунодефицита, который в 2022 году составил 196,50 млн долларов США, как ожидается, достигнет 423,5 млн долларов США к 2030 году и, как ожидается, будет претерпевать среднегодовой темп роста в 10,4% в течение прогнозируемого периода. Это указывает на то, что рыночная стоимость. «Больница» доминирует в сегменте конечного пользователя рынка тяжелого комбинированного иммунодефицита из-за увеличения числа случаев в больницах. В дополнение к информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, курируемые Data Bridge Market Research, также включают глубокий экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Объем и сегментация рынка тяжелого комбинированного иммунодефицита

Market Definition

Severe combined immunodeficiency (SCID) is rare, inherited disorders that result in major immune system abnormalities. It is caused due to the changes in the different genes responsible for the development and functioning of infection-fighting immune cells. SCID is a type of primary immunodeficiency disease which is characterized by chronic diarrhea, failure to thrive, ear infections, sinusitis, oral thrush, meningitis, skin rashes, pneumonia, among others. These disorders are considered life-threatening or fatal mostly in the first two years of a child’s life.

Global Severe Combined Immunodeficiency Market Dynamics

Drivers

• Increasing Prevalence of Severe Combined Immunodeficiency

The prevalence of severe combined immunodeficiency (SCID) is a critical factor that can influence the market for SCID treatments. SCID is a rare genetic disorder characterized by a severely compromised immune system, and its prevalence can vary by region and population

The prevalence of SCID can vary by region and population. Some genetic mutations that cause SCID are more prevalent in certain ethnic or geographic groups, which can drive the demand for acute severe combined immunodeficiency market

Moreover, population growth can lead to an increase in the number of SCID cases. A larger patient population can potentially drive market growth as the demand for treatments increases, necessitating the need for demand of treatment

• Increase in Early Diagnosis or Screening of the Disorder

Screening or early diagnosis plays an important role in saving the lives of infants. Addition of the IDF SCID Newborn Screening Campaign in the newborn screening panel of the U.S. resulted in higher awareness about the diagnosis of SICD. This can foster the demand for diagnosis of severe combined immunodeficiency cases across the globe

According to the Immune Deficiency Foundation, 13 different genetic defects can cause severe combined immunodeficiency in infants, leading to serious infections. According to scientists, gene therapy offers promising treatment for this disorder. ADA-SCID is a rare inherited disorder, also known as bubble syndrome, caused by mutation in the adenosine deaminase (ADA) gene. This type of SCID is the second most prevalent form of the disorder

Moreover, the implementation of newborn screening programs in various countries has led to the early diagnosis of SCID. Early detection allows for timely intervention and treatment, potentially improving patient outcomes and increasing the demand for SCID therapies. This shift is expected to boost the demand for severe combined immunodeficiency market

• Increasing Healthcare Expenditure

Greater healthcare expenditure, both by governments and private entities, can provide healthcare facilities with more resources to invest in advanced severe combined immunodeficiency equipment and treatments. Thus, demand for treatment has driven the development of new technologies which further fuel the growth during the severe combined immunodeficiency market in the forecast period.

Moreover, Growing awareness among healthcare providers, caregivers, and the general public about SCID and its consequences has led to more timely diagnoses and treatments. Increased awareness can drive the demand for SCID therapies. Increasing awareness about the importance of diagnosis and treatment of severe combined immunodeficiency can lead to more patients seeking medical care, which will further act as driver that will lead to the growth of the severe combined immunodeficiency market in the above mentioned projected timeframe

Opportunities

• Rising Collaborations and Investments by Leading Players

Increasing collaborations between pharmaceutical companies, research institutions, and healthcare organizations have facilitated research and development efforts for SCID treatments. These collaborations can accelerate the development and commercialization of new therapies. This will extend profitable opportunities for the severe combined immunodeficiency market players in the forecast period of 2023 to 2030

In addition, the improvements in healthcare infrastructure, particularly in emerging markets, have increased access to SCID treatments. Expansion of healthcare services and insurance coverage, which will further contribute by generating immense opportunities that will further expand the market's growth rate in the future 

Restraint/Challenge

• High Cost Associated with the Treatment

On the other hand, high cost associated with the treatment, especially gene therapies, which is a highly specialized and resource-intensive process. Ensuring affordability and equitable access to these treatments will likely to act as market restraints factor for the growth of the acute abdomen trauma market in the above mentioned projected timeframe. Moreover, developing new treatments for rare diseases such as SCID can be expensive. The cost of research, clinical trials, and manufacturing can be substantial will become the biggest and foremost challenge for the growth of the market in the forecast period of 2023 to 2030

This severe combined immunodeficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the severe combined immunodeficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

• In September 2020, DJO will release the DonJoy X-ROM Post-Op Knee Brace. The product is stated to be one of the most advanced range of motion (ROM) protection, with an improved user-friendly design for quicker and faster application and adjustment. The X-ROM brace aids patients in their recovery after ACL reconstruction and other knee procedures. It increases comfort, stability, and confidence

Global Severe Combined Immunodeficiency Market Scope

The severe combined immunodeficiency market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Classical X-linked SCID
• ADA deficiency SCID

Treatment

• Medication
• Antibiotics
• Immune Globulin Replacement Therapy
• Antifungals
• Gene Therapy
• Stem Cell Therapy
• Enzyme Therapy
• Others

Diagnosis

• Blood Tests
• New-born Screening Test
• Genetic Tests
• Others

Symptoms

• Failure to Thrive
• Ear Infections
• Chronic Diarrhea
• Sinusitis
• Oral Thrush
• Meningitis
• Skin Rashes
• Pneumonia
• Others

Dosage

• Tablet
• Injection
• Others

Route of Administration

• Oral
• Intravenous

End-Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Severe Combined Immunodeficiency Market Regional Analysis/Insights

The severe combined immunodeficiency market is analyzed and market size insights and trends are provided by type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel

The countries covered in the severe combined immunodeficiency market  report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America 

North America dominates the severe combined immunodeficiency market due to the presence of major key players, the high adoption rate of stem cell therapy and the well-developed healthcare infrastructure in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 owing to the increasing awareness about screening of rare disorders, advancement of healthcare sector and rising investments for clinical trials in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Рост инфраструктуры здравоохранения, установленная база и проникновение новых технологий

Рынок тяжелого комбинированного иммунодефицита также предоставляет вам подробный анализ рынка для каждой страны по росту расходов на здравоохранение для капитального оборудования, установленной базы различных видов продукции Рынок тяжелого комбинированного иммунодефицита, влияние технологий с использованием кривых линии жизни и изменений в сценариях регулирования здравоохранения и их влияние на рынок тяжелого комбинированного иммунодефицита. Данные доступны за исторический период с 2010 по 2021 год.

Конкурентная среда и анализ доли рынка тяжелого комбинированного иммунодефицита

Конкурентная среда рынка тяжелого комбинированного иммунодефицита содержит сведения о конкурентах. Включены сведения о компании, финансах компании, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании в применении. Приведенные выше данные относятся только к фокусу компании, связанному с рынком тяжелого комбинированного иммунодефицита.

Некоторые из основных игроков, работающих на рынке лечения тяжелого комбинированного иммунодефицита:

• AbbVie Inc. (Ирландия)
• Merck Sharp & Dohme Corp. (США)
• Pfizer Inc. (США)
• GlaxoSmithKline plc. (Великобритания)
• Melinta Therapeutics LLC (США)
• Basilea Pharmaceutica Ltd. (Швейцария)
• Tetraphase Pharmaceuticals (США)
• Paratek Pharmaceuticals, Inc. (США)
• Nabriva Therapeutics plc (Ирландия)
• Spero Therapeutics (США)
• Эбботт (США)
• F. Hoffmann-La Roche Ltd. (Швейцария)
• Mylan NV (США)
• Teva Pharmaceutical Industries Ltd. (Израиль)
• Санофи (Франция)
• Новартис АГ (Швейцария)
• Bayer AG (Германия)
• Sun Pharmaceutical Industries Ltd. (Индия)
• Ауробиндо Фарма (Индия)
• Люпин (Индия)
• SHIONOGI & Co., Ltd. (Япония)
• Cumberland Pharmaceuticals Inc. (США)
• Eli Lilly and Company (США)

SKU-67004